Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020068867 - QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE

Publication Number WO/2020/068867
Publication Date 02.04.2020
International Application No. PCT/US2019/052784
International Filing Date 24.09.2019
IPC
C07D 239/94 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
70condensed with carbocyclic rings or ring systems
72Quinazolines; Hydrogenated quinazolines
86with hetero atoms directly attached in position 4
94Nitrogen atoms
C07D 401/12 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 401/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
C07D 403/10 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
10linked by a carbon chain containing aromatic rings
C07D 413/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
413Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14containing three or more hetero rings
C07D 487/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
CPC
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 239/94
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
70condensed with carbocyclic rings or ring systems
72Quinazolines; Hydrogenated quinazolines
86with hetero atoms directly attached in position 4
94Nitrogen atoms
C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
C07D 403/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
02containing two hetero rings
10linked by a carbon chain containing aromatic rings
C07D 413/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
413Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14containing three or more hetero rings
Applicants
  • BLACK DIAMOND THERAPEUTICS, INC. [US]/[US]
  • FLOHR, Alexander [CH]/[CH]
  • MAYWEG, Alexander [US]/[US]
  • TRAINOR, George [US]/[US]
  • EPSTEIN, David M. [US]/[US]
  • O'CONNOR, Matthew [US]/[US]
  • BUCK, Elizabeth [US]/[US]
Inventors
  • FLOHR, Alexander
  • MAYWEG, Alexander
  • TRAINOR, George
  • EPSTEIN, David M.
  • O'CONNOR, Matthew
  • BUCK, Elizabeth
  • ARISTA, Luca
Agents
  • ERLACHER, Heidi A.
  • ELRIFI, Ivor
  • SUN, Xixi
Priority Data
62/736,29325.09.2018US
62/903,59220.09.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE
(FR) DÉRIVÉS DE QUINAZOLINE UTILISÉS EN TANT QU'INHIBITEUR DE TYROSINE KINASE, COMPOSITIONS, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION
Abstract
(EN)
The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).
(FR)
La présente invention concerne de nouveaux composés ou leurs sels ou stéréoisomères pharmaceutiquement acceptables de formule I en tant qu'inhibiteurs des récepteurs de tyrosine kinases (RTK), en particulier des mutants extracellulaires de récepteurs ErbB. La présente invention concerne également des procédés de préparation de ces composés, des compositions comprenant ces composés, et des procédés d'utilisation de ceux-ci dans le traitement du cancer chez des mammifères (par exemple, des êtres humains).
Latest bibliographic data on file with the International Bureau